Day 2 :
Keynote Forum
Vladimir P Torchilin
Northeastern University, USA
Keynote: Pharmaceutical nanotechnology in preparing “smart†combination preparations of RNA and chemotherapeutic drugs for multidrug-resistant cancer
Time : 09:30-10:05
Biography:
Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 60,000 citations of his papers with H-index of 107. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.
Abstract:
Tumor therapy, especially in the case of multidrug-resistant cancers, could be significantly enhanced by using siRNA down-regulating the production of proteins, which are involved in cancer cell resistance, such as Pgp or survivin. The even better response could be achieved is such siRNA could be delivered to tumors together with a chemotherapeutic agent. This task is complicated by the low stability of siRNA in the biological surrounding. Thus, the delivery system should simultaneously protect siRNA from degradation. We have developed several types of lipid-core polymeric micelles based on PEG-phospholipid or PEI-phospholipid conjugates, which are biologically inert, demonstrate prolonged circulation in the blood and can firmly bind non-modified or reversibly-modified siRNA. Additionally, these nano-preparations can be loaded into their lipidic core with poorly water-soluble chemotherapeutic agents, such as paclitaxel or camptothecin. In experiments with cancer cell monolayers, cancer cell 3D spheroids, and in animals with implanted tumors, it was shown that such co-loaded preparations can significantly down-regulate target proteins in cancer cells, enhance drug activity, and reverse multidrug resistance. In order to specifically unload such nano-preparations inside tumors, we made them sensitive to local tumor-specific stimuli, such as lowered pH, hypoxia or overexpressed certain enzymes, such as matrix metalloproteases. Using pH-, hypoxia-, or MMP2-sensitive bonds between different components of nano-preparations co-loaded with siRNA and drugs, we were able to make the systems specifically delivering biologically active agents in tumors, which resulted in significantly improved therapeutic response.
Keynote Forum
Yuri L Lyubchenko
University of Nebraska Medical Center, USA
Keynote: Critical role of membranes in nanoassembly of amyloid proteins
Time : 10:05-10:40
Biography:
Yuri L. Lyubchenko is Professor of Pharmaceutical Sciences at the University of Nebraska Medical Center, Omaha, NE, USA. His research focuses on understanding the fundamental mechanisms underlying health and disease, which are key to developing new and more effective diagnostics and medications. This primarily basic research allows him not only identify new drug targets for small molecule drugs, but it also leads to the development of the nanotools and methods to discover novel approaches for diagnostic, treatment and disease prevention and to more rapidly determine their efficacy at the molecular level.
Abstract:
Statement of the Problem: The amyloid cascade hypothesis is currently considered as the main model for a vast number of neurodegenerative diseases including Alzheimer’s, Parkinson’s, and Huntington’s diseases. Numerous studies have shown that amyloidogenic proteins are capable of spontaneous assembly into aggregates, and eventually form fibrillar structures found in amyloid or amyloidâ€like deposits. However, there is a serious complication with translating current knowledge on amyloid aggregation in vitro to understand the aggregation process in vivo. If the critical concentration for the spontaneous aggregation of Aβ peptide in vitro is in the micromolar range, physiological concentrations of Aβ are in the low nanomolar range making impossible amyloids to assemble.
Methodology & Theoretical Orientation: We discovered a novel on- surface aggregation pathway that allows for spontaneous assembly of amyloid beta peptides at the physiological concentration range. We combined experimental studies involving single-molecule time-lapse AFM imaging with all-atom molecular dynamics simulations to characterize the on-surface self-assembly process of amyloid proteins. Experimental data demonstrate that on-surface aggregation occurs in the physiological range of concentrations of the proteins. Our combined experimental and computer modeling approaches demonstrate that the on-surface aggregation is a dynamic process, so the assembled aggregate can dissociate from the surface to the bulk solution. As a result, the dissociated oligomers can play roles of seeds for aggregation in the bulk solution, or start a neurotoxic effect such as phosphorylation of the tau protein to initiate its misfolding and aggregation. Both processes can lead to neurodegeneration.
Conclusion & Significance: We posit that on-surface aggregation is the mechanism by which neurotoxic amyloid aggregates are produced under physiological conditions. A change in membrane properties leading to an increase in affinity of amyloid proteins to the membrane surface facilitates the assembly of stable oligomers. The proposed model is a significant departure from the current model as it directs the development of treatments and preventions towards approaches that control the cell membranes composition to prevent the on-surface aggregation process.
Keynote Forum
Rashid Mahmood
Surge Laboratories Private Limited, Pakistan
Keynote: Hot melt extrusion: An emerging drug delivery technology of the 21st century
Time : 11:00-11:35
Biography:
Rashid Mahmood has a master degree in Analytical Chemistry and an MS in Total Quality Management. He has 15 years of experience of Pharmaceutical Quality Operations and has participated in many international conferences as a keynote speaker. He has presented various talks in USA & China on Cleaning Validation, cGMP Guidelines, Quality Risk Management, Role of Mass Spectrometry in Pharmaceuticals and on new Drug Delivery Systems. Currently, he is working as a Senior Executive Manager Quality Operations for Surge Lab. (Manufacturer of Microencapsulated APIs, Liquid & Dry Powder Parentrals) which is the best export-oriented company of Pakistan.
Abstract:
Hot melt extrusion (HME) is emerging technology which is gaining high importance in the pharmaceutical industry as a novel technique for the preparation of various dosage forms and drug delivery systems, for example, granules and sustained-release tablets. It is a fast-growing technology platform that is utilized to solve difficult formulation challenges, primarily in the area of solubilization. Due to fast processing, a high degree of automation, the absence of solvents, simple and continuous operation and ability to process poorly compactable material into tablet form are some of the main advantages offered over conventional processing by this emerging technique. Applications of HME in the pharmaceutical industry continues to grow and the recent success of this technique has made it a useful tool of consideration as a drug delivery solution. The use of hot-melt extrusion (HME) within the pharmaceutical industry is steadily increasing, due to its proven ability to efficiently manufacture novel products. HME involves the application of heat, pressure, and agitation through an extrusion channel to mix materials together, and subsequently forcing them out through a die. Twin-screw extruders are most popular in solid dosage form development as it imparts both dispersive and distributive mixing. It blends materials while also imparting high shear to break-up particles and disperse them. HME extrusion has been shown to molecularly disperse poorly soluble drugs in a polymer carrier, increasing dissolution rates and bioavailability.
Keynote Forum
Arkesh Mehta
OncoBindi Therapeutics, USA
Keynote: Aayush BioSphere: Clinical outcome focused platform for precision therapeutic development
Time : 11:35-12:10
Biography:
Arkesh Mehta serves as Chief Executive Officer of OncoBindi Therapeutics and a member of the company’s Board of Directors, bringing more than 30 years of experience in the biopharmaceutical industry to the company. He joined OncoBindi in 2016 as the company’s Founding Chief Executive Officer. He joined OncoBindi from Chikujee Therapeutics, where he served as Chairman & Chief Executive Officer, since 2014, prior to its acquisition by a group of investors from Germinate 360. Prior to joining Chikujee Therapeutics, he held senior management positions at Avanti Nano Sciences, BPI Technologies, and Avanti Therapeutics. In addition, he was a key member of the strategic leadership committees for Avanti Therapeutics and it's North American and worldwide partnerships. Prior to joining Avanti Therapeutics, he was the first CTO of the Biotechnology Industry Organization. He has held leadership program management positions at Office of R&D US EPA, Office of the Commissioner US FDA. His academic appointments include the head of Molecular biology section at Virginia State University and Associate Professor of Research at Cornell University. He received a PhD. in Microbiology from M.S. University and post-doctoral training from University of Mississippi Medical Center in Jackson, Mississippi.
Abstract:
While major progress has been achieved in research and development, the majority of new therapies continue to fail in human trials, despite showing promise in preclinical testing. As the Big Pharma model of producing a drug from soup to nuts has proven to be less effective at getting novel drugs to market, the drug discovery and development process have become fragmented. Additionally, as the science and regulatory requirements get more complex there is a need for more depth of expertise in each of these segments, which plays to the strengths of innovative companies. The years- to decades-long process can be complex, and there is nearly always a moment of uncertainty that a drug will succeed in the next phase of development. This long development pipeline faces increasing costs and additional challenges, including the lack of predictive validity of current animal models, insufficient knowledge regarding underlying mechanisms of disease, patient heterogeneity, lack of targets and biomarkers, a high rate of failed clinical trials, and regulatory challenges. To better understand how these challenges, create bottlenecks in the development pipeline, a cost-efficient and unified drug development architecture are critical for the success of sustainable biopharma companies.
This presentation introduces Aayush Biosphere’s Hyperscale™ Technology and the two ways it may be implemented: (a) Aayush BioSphere NanoBindi™ technology is a scale-out infrastructure based on the Patient's clinical preferences. (b) Aayush BioSphere NanoBindi™ technology is a clinical outcome focused solution that tightly integrates drug API (s), cell-specific targeting, on demand controlled release and full lifecycle management and analytics into a single platform across the precision therapeutic development. Built on Avanti Therapeutic's industry-leading technology, it allows Biopharma companies to significantly decrease complexity and cost while increasing both scalability and product pipeline agility.
Keynote Forum
Jim Jingjun Huang
Ascendia Pharmaceuticals LLC, USA
Keynote: 12:10-12:45
Time : 12:10-12:45
Biography:
Jim Huang founded Ascendia after years of pharmaceutical R&D experience at Pfizer (ex-Wyeth), Baxter, AstraZeneca, and Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. He holds a Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with Professor Joseph B. Schwartz.
Abstract:
There are many significant hurdles for a pharma or biotech company to overcome during the development process. The high failure rate in drug development shows that only 1 in 5,000 discovery compounds will reach the market, and one in every five drug candidates will gain approval. A dramatic increase in the percentage of the new chemical entities (NCEs) with poor physical, chemical, and biopharmaceutical properties (BCS II and IV) 4 in the drug pipeline has played a significant role in attributing to those high failure rates and increase in development timelines. About 50% of drugs on the market and nearly 90% of molecules in the discovery pipeline are poorly water-soluble. Administration of those compounds by parenteral route without causing injection site reaction and systemic toxicity effects constitutes another barrier. Numerous drugs associated with poor solubility and low bioavailability have been successfully formulated into drug products for clinical studies by a suite of available formulation technologies. Many marketed drugs have been successfully reformulated to improve efficacy, safety and patient compliance using the NDA 505(b)(2) regulatory pathway. Revitalization of older marketed drug products using innovative drug delivery technologies or platforms can provide new marketing exclusivity and new patent protection, and thus offer an effective tool for product life cycle management.
Keynote Forum
Raymond C Jagessar
University of Guyana, Guyana
Keynote: Antimicrobial activity of the ethanolic and aqueous extract of passion fruit (Passiflora edulis), in the absence and presence of transition metal salts
Time : 12:45-13:20
Biography:
Raymond C. Jagessar obtained his BSc (Distinction) in Chemistry/Biology from the University of Guyana (1992) and his Ph.D. from the UK (1995). He held three Post-Doctoral Research Fellowships (PDF) at various universities overseas. He has also won several international awards, amongst them are Chartered Chemist, CChem and Fellow of the Royal Society of Chemistry, FRSC, UK, Research and traveling Grants etc. His research interests are broad, covering the spectrum of Pure and Applied Chemistry, Chemical Biology and Pharmaceutical Chemistry. He has published over eighty (80) research articles, five book chapters and presented at conferences: locally and internationally. He is currently Professor in Chemistry at the University of Guyana (South America).
Abstract:
The aqueous and ethanolic extract of Passion fruit (Passiflora edulis Sims) was investigated in the absence and presence of transition metal salts using the Disc Diffusion Assay under aseptic conditions. For the ethanolic extracts, 1-3, the highest AZOI of 153.9mm2 was induced by the sample (1), 0.015g/ml of the extract against C. albicans. The lowest AZOI of 15.9mm2 was also induced by sample 3, 0.1g/ml of the ethanolic extract against K. pneumoniae. There seems to be a general increase in AZOI as the concentration of ethanolic extract increases. From the ethanolic extract, a white isolate crystallized and its antimicrobial activity was investigated at an increasing concentration (sample 4-5). For sample 4-5, the highest AZOI of 149.5mm2 was induced by the aqueous solution at a concentration of 0.026g/ml against P. aeruginosa. The lowest AZOI of 30.7mm2 was induced by the white isolate at a concentration of 0.052g/ml against K. pneumoniae. For sample 6 and 7, 0.1g of Zn (OAc)2.2H2O in 10ml aqueous extract and 1.0g of Zn(OAc)2.2H2O in 10ml of aqueous extract, it was observed that the highest AZOI of 67.2mm2 was observed against E. coli. whereas the lowest AZOI of 21.6mm2 was observed against C. albicans. The AZOI induced by sample 8, 1.0g of Zn (OAc)2.2H2O in 10ml of aqueous solution is greater than sample 7, suggesting that Zn(OAc)2.2H2O augment the antimicrobial activity of the aqueous passion fruit extract. Antimicrobial selectivity was also observed. For example, against S. aureus, sample (1) exhibit AZOI of 32.2mm2 whereas against C. albicans, AZOI of 153.9mm2 was observed. For all experiments conducted, antimicrobial activity seems to be less than that of the standard antibiotics: Ampicillin and Nystatin. Nevertheless, the ethanolic and aqueous extracts of green passion fruit can be used as a natural antibiotic against a range of bacteria-induced diseases.
- Nanomedicine and Nanobiotechnology | Applied Pharmaceutical science | Pharmaceutical Formulations | Design and Characterization of Nano Drug Systems | Computational Studies in Nanoparticles | Smart Drug Delivery Technology
Location: New York, USA
Chair
Oara Neumann
Rice University, USA
Co-Chair
Arend L Mapanawang
Stikes Halmahera, Indonesia
Session Introduction
Yucel Baspinar
Ege University, Turkey
Title: Ultrasound sensitive nanobubbles containing Paclitaxel, YM155, and siRNA as gene carriers for the therapy of lung cancer
Time : 13:45-14:10
Biography:
Yucel Baspinar studied Pharmacy at Free University Berlin, Germany and started as a research assistant at the same Institute in the Department of Pharmaceutical Biochemistry, Biopharmacy and Biotechnology with his Ph.D. thesis (2005-2009) entitled as “nano and microemulsions for the topical application of poorly soluble immune suppressive". After his Ph.D., he worked as Post-Doc for Prof. Burkhard Kleuser in the same Faculty, Department of Pharmacology and Toxicology in an EFRE (European Fund for Regional Development) project entitled with “Nanocarriersystems for dermatotherapy" (2009-2010). 2011-2013 he worked as Head of Drug Development and Quality Control Laboratory and in Biosimilar Laboratory in the Center for Drug Research & Development and Pharmacokinetic Applications at the Ege University in Izmir, Turkey. 2013- now he is Assistant Professor in the Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Ege University. The major research areas are Pharmaceutical Formulations of protein drugs and monoclonal antibodies prepared by the recombinant DNA technology and biosimilars
Abstract:
23% of the worldwide cancer-related death rate is due to lung cancer, more than the sum of breast, colon and prostate cancer. A great deal in common for almost each cancer type, including lung cancer, is an overexpression of the apoptosis inhibitor survivin. For improving the chemotherapy several strategies were performed. Previously, ultrasound sensitive nanobubbles containing paclitaxel, survivin-siRNA and survivin inhibitor sepantronium bromide (YM155), respectively, were developed against A549 lung cancer cells. The paclitaxel-loaded nanobubbles had a particle size of 309nm and a zeta potential of 34mV, the paclitaxel and YM155 loaded nanobubbles had a particle size of 57nm and a ZP of 47mV, while the PTX and siRNA loaded nanobubbles had a particle size of 252nm and a ZP of 27mV. The cytotoxicity studies revealed promising results and encouraged for further investigations. The aim of this study was to evaluate the siRNA complexation, serum stability, gene silencing efficiency, and Apoptosis. The developed nanobubbles were able to form a complex with survivin-siRNA and protected the siRNA from nucleases. The gene silencing efficiency and Apoptosis were evaluated, with and without ultrasound exposure, by qPCR and Apoptosis kits and showed that NB formulations were able to silence survivin expression and induce apoptosis in the A549 cell line.
Acknowledgement: This study has been financially supported by TUBITAK under grant code 116S213
Andrew J Kobets
Children's Hospital, USA
Title: Paramagnetic nanoparticles conjugated with lipopolysaccharide for blood-brain barrier disruption in a model of glioblastoma
Time : 14:10-14:35
Biography:
Abstract:
Background: Glioblastoma (GBM) is the most aggressive primary adult brain tumor with only 14.6 months of median survival. Carrier nanoparticles have emerged as a novel strategy for chemotherapeutic delivery, yet penetration of the blood-brain barrier (BBB) and tumor retention remain significant hurdles. The evolution of paramagnetic nanoparticles (PMNPs) shows promise for reliable, magnetically-targeted drug delivery, and coupled with a lipopolysaccharide-coating (LPS-PMNPs) allows for concurrent, reversible BBB disruption.
Jigisha P Badheka
PDU Medical College, India
Title: Smart drug delivery systems in anaesthesia an Indian scenario
Time : 14:35-15:00
Biography:
Jigisha P Badheka MD Anaesthesiology Working as an Associate Professor, In Department of Anaesthesiology, PDU Medical College, Rajkot Instructor for ACLS, BLS. PG Certificate course QM & AHO (Quality Management & accreditation of health Care organization) by AHA, and Disaster Management course by IGNOU. Wide experience in all the fields of anesthesia, Tutor for 11/2 yrs 1995-97 Class 1 anaesthesiology for 3 yrs.1997-99 Assistant professor for 7 yrs.1999- 2007 Associate professor since 2007 till date. Internal and external examiner since last 10yrs. Publications for national and international journals. Speaker for state and national conference.
Abstract:
The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. Novel Drug Delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. Whereas the Targeted drug delivery, sometimes called smart drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. It has advantages like the reduction in the frequency of the dosages, having a more uniform effect of the drug, reduction of the adverse effect of drugs and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages. Newer intravenous drugs used for TIVA having a short duration of action so, fast recovery to maintain plasma level and to achieve the constant targeted level of sedation, analgesia, and anaesthesia targeted release system is useful which releases the drug in a dosage form. I will discuss a review of target controlled infusion total intravenous anaesthesia in India.
Selvie S Ticoalu, Mathen zebedeus
AKBID Makariwo, Indonesia
Title: The effect of granting Gedi leaf (Abelmoschus manihot L.) against blood sugar levels in pregnant women in North Halmahera
Time : 15:00-15:25
Biography:
Selvie S. Ticoalu is Gynecology specialists in Bandung, West Java at the Advent Bandung Hospital and teaches as lecturers AKBID Makariwo
Abstract:
Diabetes Mellitus is one of the causes of mortality and morbidity in all countries, where there are 3.5-4.3% of the world's population affected by diabetes mellitus. Based on data from the World Health Organization (WHO), the number of people with diabetes mellitus in the world reaches 285 million and is estimated to be more than 430 million by 2030. Type 2 diabetes mellitus (not insulin-related) is the most common, 95% of all cases of diabetes mellitus. The aim of the study was to determine the effect of giving Gedi leaf decoction (Abelmoschus manihot L.) to decrease blood sugar levels in pregnant women in northern Halmahera in 2018. The research method used was quasi-experimental with the design of one group pretest-posttest. The population in this study were 10 pregnant women at the Tiberias Tobelo clinic, with a sampling technique using a total sampling of 10 pregnant women with blood sugar. The results of the study showed that the average blood sugar levels in pregnant women before giving the decoction of Gedi leaves (Abelmoschus manihot L.) was 109.79mg/dL, and the average value of blood sugar in pregnant women after Gedi leaf decoction (Abelmoschus manihot L.) is 108.12mg/dL, the results of the analysis test with Paired sample T-Test obtained a significance value (p) of 0.002 significance value p<0.05. The conclusion that the average decrease in blood sugar levels in pregnant women is 1.67mg/dL, the statistical test results obtained that the effect of giving the leaves of Gedi leaves (Abelmoschus manihot L.) to pregnant women with blood sugar.
David Guerrero
Children's Hospital of Philadelphia, USA
Title: Nanocarrier with reversibly hydrophobized co-drugs for treating aggressive neuroblastoma
Time : 15:25-15:50
Biography:
David Guerrero in 2015, joined the research team of Dr. Michael Chorny at The Children’s Hospital of Philadelphia working on new drug delivery systems for treating arterial restenosis and cancer. Among other projects, he has worked on developing new strategies to target and treat aggressive pediatric solid tumors using polymeric nanoparticles formulated with novel mutual prodrugs (co-drugs). His research has contributed to a recent paper in Clin Cancer Res on enhanced intratumoral delivery of camptothecin-mitocan co-drugs for the treatment of high-risk neuroblastoma.
Abstract:
Nanomedicine-based delivery strategies have the potential to improve the therapeutic performance of a variety of anticancer agents. However, their clinical translation has been hampered by difficulty in achieving stable drug entrapment within nanocarriers, together with controlled release directly in the tumor tissue. In this study, we evaluated an experimental strategy that combines in situ activatable camptothecin-mitocan fusion molecules (co-drugs) and sub-100nm sized biodegradable nanoparticles (NP) derived using a nanoprecipitation-based formulation process. A series of reversibly hydrophobized co-drugs of a potent camptothecin agent, SN38, with tocol mitocans exhibiting a range of hydrolytic activation rates were encapsulated in 85±36nm sized NP with high efficiency (93±2% entrapment yield) using the optimized procedure. NP loaded with a phenolic ester co-drug were found to be most effective against both chemo-naïve and chemoresistant NB cells under conditions modeling different levels of exposure experienced by NB cells within the tumor. Phenolic carbonate and aliphatic ester designs were found to be notably less efficient. In an in-vivo model of previously untreated disease [IMR-32 orthotopic xenograft], nanocarriers with phenolic ester co-drug administered over 4 weeks [10mg/kg, twice a week] induced tumor regression and completely inhibited tumor growth over a 26-week period. The same co-drug/nanocarrier formulation tested against multidrug-resistant NB [BE(2)-C orthotopic xenograft] potently suppressed tumor growth and extended animal survival up to 7 weeks, in contrast to a marginal and transient effect of the clinically used SN-38 precursor, irinotecan [event-free survival of 3 weeks vs. 2 weeks in ‘no treatment’ and drug-free NP groups]. We conclude that camptothecin-mitocan co-drugs can be rationally designed as therapeutic cargoes for nanocarrier-based therapy of aggressive malignancies. The co-drug/nanocarrier combination strategy proven effective in preclinical testing experiments in this study holds promise as a treatment for high-risk NB and potentially can be extended to other pediatric and adult solid tumors
Fremiot J Mascarenhas
Bhavnagar Medical Association, India
Title: Transdermal drug delivery system
Time : 16:10-16:35
Biography:
Fremiot J.Mascarenhas, Qualifications: MBBS. From M. P. Shah Medical College, Jamnagar. Diploma in Anaesthesiology from M.P.Shah Medical College, Jamnagar. Currently practicing as a consultant Anaesthesiologist in city of Bhavnagar, Gujarat,India since last 25 years. The main field of interest are laparoscopy and Bariatric Anaesthesia and postoperative pain relief Post held: Secretary, Bhavnagar Anaesthesiologist' Association from 2011 to 2017. Presently Hon. Secretary, Bhavnagar Medical Association from 2015. Successfully Organized West Zone Anaesthesia Conference-ISACONGUJARAT2016 at Bhavnagar as Organizing Secretary
Abstract:
Transdermal drug delivery refers to a system in which a fixed amount of drug is delivered across the skin over a period of time to the bloodstream so as to maintain a therapeutic level of that drug. This method of drug delivery is painless and has excellent compliance in both pediatric and geriatric age group as it is pain-free and hassle free and does not need any specialized equipment for its use. Transdermal method of drug delivery has a great many advantages over other conventional routes of drug administration such as oral, intramuscular, intravenous. Medication applied in form of a fixed-dose adhesive patch that is applied to the skin surface and is absorbed through the pores of the skin and delivered in the bloodstream in a controlled way. The main objective of this painless route of administering a drug is to provide a therapeutic dose level of drug in the bloodstream with the minimal patient to patient variation while limiting the side effects if the same were to be administered by any other route.
Gershon Golomb
The Hebrew University of Jerusalem, Israel
Title: Monocyte-mediated delivery systems for theranostic applications in inflammatory-associated disorders
Time : 16:35-17:00
Biography:
Gershon Golomb is a Full Professor of Pharmaceutics at the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. His works for many years has focused on drug delivery systems. His studies have developed controlled-release implantable and injectable drug/gene delivery systems; from hypothesis to in-vivo studies. He is an expert in targeted nanoparticles (polymeric-based and liposomes) for the treatment of cancer, cardiovascular disorders, and inflammatory-associated pathologies.
Abstract:
The mononuclear phagocytic system (MPS) is a part of the immune system that consists of phagocytic cells, primarily monocytes, and macrophages. Both circulating monocytes and neutrophils phagocyte debris, and foreign particles in the blood including particulate drug delivery systems. Inflammation characterizes several pathological disorders including cardiovascular disorders and cancer, and the inflammatory cascade involves significant infiltration of phagocytic cells. The propensity of monocytes for rapid phagocytosis of particulate matter provides a rational approach for delivering drugs in inflammatory-associated disorders. In this presentation, we will review therapeutic as well as diagnostic approaches mediated via specially designed nanoparticles (NPs), which are avidly internalized by circulating monocytes. Monocytes can serve as a courier of specific NPs to the CNS, bypassing the blood-brain barrier (BBB), effectively transporting drugs that are brain- impermeable. Liposomal delivery of quantum dots (QDs) enables an efficient fluorescent signal with no toxicity, in animal models of cardiovascular and cancer disorders. In addition, we will present recent results, unpublished, on the accumulation and retention of QDs in a mammary carcinoma model, following systemic administration, in comparison to passive delivery by the enhanced permeability and retention effect (EPR). The developed NPs delivery systems represent a novel approach for effective theranostic of inflammatory-associated disorders including cardiovascular, brain, and cancer diseases.
- Applied Pharmaceutical science | Pharmaceutical Formulations | Smart Drug Delivery Technology
Location: New York, USA
Chair
Vladimir P Torchilin
Northeastern University, USA
Co-Chair
Hendry Izaac Elim
Pattimura University, Indonesia
Session Introduction
Arend L Mapanawang
Stikes Halmahera, Indonesia
Title: Antioxidant activity and golobe level anticancer (Zingiberaceae) and leaves pangi
Time : 14:20-14:45
Biography:
Arend L Mapanawang has completed his Ph.D. from the Department of Pharmacy, College of Health Sciences, Yayasan Medika Mandiri Foundation, Halmahera, Indonesia. He is the Director of College of Health Sciences (STIKES Halmahera), Medika Mandiri Foundation, Halmahera, Indonesia. He is the Head of Internal Medicine Departement of Bethesda Hospital in Tobelo North Halmahera, North Moluccas.
Abstract:
Cancer is one of the diseases that the death rate is high because it has not found a drug that heals it completely. Researches continue to be developed incorrectly one is to develop a (Zingiberaceae) and leaf pangi (pangiense) vegetables consumed daily in Minahasa North Sulawesi by MTT and HPLC test methods golobe 6.5mg/ml and pangi 150mg/ml performed to see antioxidant activity and anticancer, can be seen the result that encourages use as protection or prevention is consumed as a health supplement either as an antioxidant or serves as a precaution against a variety of free radicals that have the potential to trigger the cells cancer in the body. FTIR test and spectrometer analysis and MTT Test, with the result of comparison of 1307- Fori 7/7 VS MCF-7 with IC50 (µg/ml) 1307,015 with positive control of cisplatin IC50 (µg/ml) 8,028. This shows golobe provides low activity but as supplements are very useful for protection or prevention. Likewise with a combination of pangi and golobe (dry simplicia) IC50 (µg/ml) 5860,470. This shows activity is weak but when given each IC50 golobe has more activity strong for cancer activity. At FTIR test leaf pangi has the highest peak 3510,6, intensity 16,36, base (H) 3747,85, base (L) 3497,09, area 141,06, Corona 113,25. Pangi leaves also have activity antioxidant and anticancer and has an antiretroviral activity that the herbs are from the grass become a new hope for prevention and even treatment in the future come.
Maykel A Kiling
Stikes Halmahera, Indonesia
Title: Identification of pentacosane compounds contained in the methanol golobe extract (Hornstedtia alliacea) in North Halmahera
Time : 14:45-15:10
Biography:
Maykel A. Kiling is Research lecturer and study program chairman at STIKES Halmahera
Abstract:
Golobe halmahera (Hornstedtia alliacea) is one type of farmer that has health benefits. The use of golobe halmahera is a source of energy when hunting, used when there are injuries and infections and this plant grows in the tropics including Halmahera. This research was conducted to identify chemical compounds contained in extra acids of methanol golobe (Hornstedtia alliacea). The design of this study was purely experimental conducted at the STIKES Halmahera pharmacy laboratory. The separation technique is maceration using methanol as a liquid dancer and the gas chromatography-mass spectrometry method is used to identify the compounds contained in the golobe halmahera methanol extract. The results showed that golobe halmahera contained alpha-cubebene 2.04%, myristaldehyde 1.33%, ethyl (9Z) -9-octadecenoate 2.13%, tricosane 3.78%, heptadecane 6.75%, pentacosane 28, 29%, heptafluorobutanoic acid, 3.15% heptadecyl ester, ethanol, 2- (octadecyloxy) 14.76%, all-trans-squalene 2.55%, 9-tricosane 6.10%, heptadecane10.05%, 17- hexadecyltetratriacotane 1.94%, (9Z) -9-tricosane 7.00%, benzenamine 2,3,4,5,6-penthacloro 7,96%.
Muhammad Jehangir
NovaMed Pharmaceuticals (Pvt) Ltd., Pakistan
Title: Pharmaceutical impurity analysis of raw materials and final product by using analytical techniques
Time : 15:10-15:30
Biography:
Muhammad Jehangir has 13 years diversified experience of Quality Control, Quality Assurance, Registration Affairs, Product development and Pharmaceutical manufacturing, Process Planning, Method development, Method validation, Statistical Methodology, Process & Cleaning Validation, Equipment Validation etc. Certificate Courses on cGMP, cGLP, Process Validation, CTD Documents, ISO 9001:2008, 13485-2003,14001-2004 have strong scientific, analytical, statistical, managerial and training skills. Currently, he is working as a Senior Manager Quality Control and validation for Novamed Pharmaceuticals. It is toll manufacturing-oriented company, manufacturing of companies like Getz Pharma, ICI, SEARLE, Macter, Ray, and for Sanofi-Aventis. He is also looking after the Quality of Novamed Healthcare, the nutraceutical and cosmeceutical manufacturing plant.
Abstract:
The evaluation of pharmaceutical raw materials and finished products for impurities and degradation products is an essential part of the drug development and manufacturing testing process. Additionally, toxicological information must be obtained on any drug-related impurity that is present at a concentration of greater than 0.1% of that of the active pharmaceutical ingredient (API). In pharmaceutical QC and manufacturing, impurity analysis has traditionally been performed by HPLC with UV, PDA, or MS detection. As it is essential to detect and measure all of the impurities in the sample, it is necessary to have a high-resolution separation process. This usually involves long analysis times resulting in low throughput. As candidate pharmaceutical compounds become more potent and are dosed at lower and lower levels, ever more sensitive assays are needed to detect and measure impurities. The low throughput of HPLC can become the rate-limiting step in product release testing or process evaluation. Since much of the process of impurity identification involves the coupling of LC to sophisticated MS, any reduction in analysis time will result in more efficient use of these significant investments. Analytical technology advances such as UPLC and UPC offer significant improvements in throughput and sensitivity, with benefits to the process of product release and identification of drug-related impurities. The most characteristic feature of the development in the methodology of pharmaceutical and biomedical analysis during the past 25 years is that HPLC became undoubtedly the most important analytical method for identification and quantification of drugs, either in their active pharmaceutical ingredient or in their formulations during the process of their discovery, development, and manufacturing.
Muhammad Shahid Khan
NovaMed Pharmaceuticals (Pvt) Ltd., Pakistan
Title: Formulation development and in-vitro characterization of orodispersible tablets of Piroxicam and Lidocaine HCl for use in dental pain
Time : 15:30-15:50
Biography:
Muhammad Shahid Khan has got more than 18 years of experience in the pharmaceutical industry in different posts. He is currently working as Plant Manager in NovaMed Pharmaceuticals (Pvt) Ltd., a local firm but also manufacturing products for many multinational companies like Sanofi Aventis, ICI, Getz Pharma, and Searle. He is overall responsible for the whole plant. He has attended many training workshops, exhibitions and technical seminars in Pakistan and abroad. He has got training from France. He has visited many countries of the world for training and to attend exhibitions.
Abstract:
The purpose of this research study was formulation development and in-vitro characterization of orodispersible tablets of Piroxicam and Lidocaine HCl along with the development and validation of the novel method of simultaneous estimation of both the drugs on HPLC. The aim was to develop a product that will provide immediate relief from the pain of dental origin, due to the local action of lidocaine in the mouth and also produce long-lasting analgesia by piroxicam after absorption. Orodispersible tablets of Piroxicam and Lidocaine HCl were developed by direct compression method. FTIR spectroscopy was used to study drug-drug and drugs-excipients compatibility. The FTIR spectra showed that there was no interaction between the two drugs and also between the drugs and excipients which proved that all the ingredients are compatible. The assay method for simultaneous estimation of both the drugs on HPLC was developed successfully. The developed method was also validated by following ICH guidelines.